June 2012. Volume 8. Number 2

Introducing a new serogroup B meningococcal vaccine with routine infant vaccinations. A step forward

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S et al.; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573-82.
Reviewers: Juanes de Toledo B1, Ruiz-Canela Cáceres J2.
1 Equipo de Atención Primaria El Espinillo. Área 11. Madrid. España.
2CS Virgen de África. Sevilla. España.
Correspondence: Blanca Juanes de Toledo. Email: blancajuanes@telefonica.net
Reception date: 17/04/2012
Acceptance date: 06/05/2012
Publication date: 23/05/2012

Abstract

Authors’ conclusion: a 4CMenB vaccine is immunogenic against reference strains when administered with routine vaccines at 2, 4 and 6 or at 2, 3 and 4 months of age, producing minimal interference with the response to routine infant vaccinations.

Reviewers’ commentary: randomized controlled trial, to determine both the immunogenicity of a new multi-component serogroup B meningococcal vaccine, as tolerability after its administration with or without routine vaccines; as well as the relationship between adverse effects and the study vaccine. More than 99% of participants had a protector immune response against two of its four components, with mild immunologic interference with some of systematic vaccine antigens (pertussis and serotype 6b pneumococcal). Fever was seen in more than 75% cases, and serious adverse events in 10% of the participants. Its long-term protection and its real clinical effectiveness are unknown.

How to cite this article

Juanes de Toledo B, Ruiz Canela J. Un paso más para la vacuna frente al meningococo B dentro del calendario vacunal. Evid Pediatr. 2012;8:37.

AVC | Critically appraised articles

Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S et al.; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573-82.
Reviewers: Juanes de Toledo B1, Ruiz-Canela Cáceres J2.
1 Equipo de Atención Primaria El Espinillo. Área 11. Madrid. España.
2CS Virgen de África. Sevilla. España.
Correspondence: Blanca Juanes de Toledo. Email: blancajuanes@telefonica.net
Reception date: 17/04/2012
Acceptance date: 06/05/2012
Publication date: 23/05/2012

How to cite this article

Juanes de Toledo B, Ruiz Canela J. Un paso más para la vacuna frente al meningococo B dentro del calendario vacunal. Evid Pediatr. 2012;8:37.

References

  1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(suppl 2):B51-B63.
  2. Cohn AC, Messonier NE. Inching toward a serogroup B meningococcal vaccine for infants. JAMA. 2012;307(6):614-5.
  3. Holsta J, Martin D, Arnoldc R, Campa Huergod C, Philipp Ostere, O’Hallahanf J et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27S:B3-B12.
  4. Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol. 2009;38:413-8.
  5. Santaolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A et al. Immunogenicity and tolerability of a multicomponent meningococcal serogrop B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617-24.
23/05/2012

Linked Comment